This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effect of the Enteric Hormone Glucagon-Like Peptide (GLP-2) on the Intestinal Blood Flow in Patients With Short Bowel Syndrome

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2008 by Glostrup University Hospital, Copenhagen.
Recruitment status was:  Enrolling by invitation
Information provided by:
Glostrup University Hospital, Copenhagen Identifier:
First received: May 5, 2008
Last updated: May 6, 2008
Last verified: May 2008
The aim of the study is to investigate the effect of the enteric hormone Glucagon-like Peptide (GLP-2) on patients with short bowel syndrome

Condition Intervention
Short Bowel Syndrome Drug: GLP-2 Drug: Placebo

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Single Blind (Participant)
Primary Purpose: Basic Science
Official Title: GLP-2 Mediated Increased SMA Blood Flow in Patients With Short Bowel Syndrome

Resource links provided by NLM:

Further study details as provided by Glostrup University Hospital, Copenhagen:

Estimated Enrollment: 8
Arms Assigned Interventions
Placebo Comparator: 2
subcutaneous isotonic saline
Drug: Placebo
Active Comparator: 1
subcutaneous GLP-2
Drug: GLP-2
450 nmol subcutaneous

Detailed Description:
previous studies have shown that GLP-2 increases mesenteric blow flow, we wish to examine the effect of subcutaneus GLP-2 on patients with short bowl syndrome. The patients will single blinded been given 450 nmol GLP-2 and isotonic saline in order to act as their own reference.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • clinical diagnose of short bowel syndrome 4 month of stable fase

Exclusion Criteria:

  • activity in IBD
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00673751

Glostrup University Hospital
Glostrup, Region Hovedstaden, Denmark, 2600
Sponsors and Collaborators
Glostrup University Hospital, Copenhagen
  More Information

Responsible Party: Lasse Bremholm, Dept. of gastroenterology, Glostrup Hospital, University of Copenhagen Identifier: NCT00673751     History of Changes
Other Study ID Numbers: H-A-2008-032
Study First Received: May 5, 2008
Last Updated: May 6, 2008

Keywords provided by Glostrup University Hospital, Copenhagen:
mesenteric blood flow
short bowel syndrome
Glucagon-Like Peptide 2

Additional relevant MeSH terms:
Short Bowel Syndrome
Pathologic Processes
Malabsorption Syndromes
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Postoperative Complications
Glucagon-Like Peptide 1
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Incretins processed this record on July 21, 2017